FamiCord AG (ETR:V3V)
Germany · Delayed Price · Currency is EUR | Market Cap | 71.64M +0.2% |
| Revenue (ttm) | 88.17M +7.3% |
| Net Income | -6.30M |
| EPS | -0.36 |
| Shares Out | 17.43M |
| PE Ratio | n/a |
| Forward PE | 137.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,447 |
| Average Volume | 1,437 |
| Open | 4.100 |
| Previous Close | 4.150 |
| Day's Range | 3.900 - 4.190 |
| 52-Week Range | 3.800 - 7.650 |
| Beta | 0.63 |
| RSI | 17.98 |
| Earnings Date | Apr 30, 2026 |
About FamiCord AG
FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces and manufactures viral vectors and CAR-T cells. In addition, the compa... [Read more]
Financial Performance
In 2025, FamiCord AG's revenue was 88.17 million, an increase of 7.29% compared to the previous year's 82.18 million. Losses were -6.30 million, -48.06% less than in 2024.
Financial StatementsNews
Vita 34 & FamiCord AG: 2025 Preliminary Results & 2026 Outlook
FamiCord reports solid 2025 results and cautious 2026 guidance, balancing efficiency gains with softer demand and rising geopolitical and macroeconomic risks.